Aradigm logo

ARDMQ - Aradigm Share Price

$0.046 0.0  0.0%

Last Trade - 29/06/20

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £3.15m
Position in Universe th / 6633
Unlock ARDMQ Revenue
Relative Strength (%)
1m -8.95%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
1.01 9.72 33.6 23.4 0.20 14.5 0.040 0.071 +70.4%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2018, AradigmCorporation revenues decreased 83% to $2M. Net lossincreased 87% to $12.2M. Revenues reflect Contract revenue- related party decrease of 87% to $1.6M, Contract revenuedecrease of 27% to $176K. Higher net loss reflects Interestexpense increase of 10% to $3.2M (expense), Other income(expense) decrease from $17K (income) to $43K (expense),Interest Income decrease of 63% to $27K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ARDMQ Revenue Unlock ARDMQ Revenue

Net Income

ARDMQ Net Income Unlock ARDMQ Revenue

Normalised EPS

ARDMQ Normalised EPS Unlock ARDMQ Revenue

PE Ratio Range

ARDMQ PE Ratio Range Unlock ARDMQ Revenue

Dividend Yield Range

ARDMQ Dividend Yield Range Unlock ARDMQ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARDMQ EPS Forecasts Unlock ARDMQ Revenue
Profile Summary

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated January 30, 1991
Public Since June 20, 1996
No. of Shareholders: 61
No. of Employees: 23
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OTC Markets Group
Shares in Issue 15,219,793
Free Float (0.0%)
Eligible for
ARDMQ Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARDMQ
Upcoming Events for ARDMQ
Frequently Asked Questions for Aradigm
What is the Aradigm share price?

As of 29/06/20, shares in Aradigm are trading at $0.046, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Aradigm share price performed this year?

Shares in Aradigm are currently trading at $0.046 and the price has moved by -61.67% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aradigm price has moved by -69.44% over the past year.

What are the analyst and broker recommendations for Aradigm?

Of the analysts with advisory recommendations for Aradigm, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aradigm is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Aradigm next release its financial results?

Aradigm is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-09-30
What is the Aradigm dividend yield?

Aradigm does not currently pay a dividend.

Does Aradigm pay a dividend?

Aradigm does not currently pay a dividend.

When does Aradigm next pay dividends?

Aradigm does not currently pay a dividend.

How do I buy Aradigm shares?

To buy shares in Aradigm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aradigm?

Shares in Aradigm are currently trading at $0.046, giving the company a market capitalisation of £n/a.

Where are Aradigm shares listed? Where are Aradigm shares listed?

Here are the trading details for Aradigm:

Country of listing: United States
Exchange: OTC
Ticker Symbol: ARDMQ
What kind of share is Aradigm?

We were not able to load our ranking data for Aradigm

Is there a Aradigm share price forecast 2021?

We were not able to load any forecast data for Aradigm.

How can I tell whether the Aradigm share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aradigm. Over the past six months, the relative strength of its shares against the market has been -35.52%. At the current price of $0.046, shares in Aradigm are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aradigm PE Ratio?

We were not able to find PE ratio data for Aradigm.

Who are the key directors of Aradigm?

We were unable to find the directors for Aradigm.

Who are the major shareholders of Aradigm?

Here are the top five shareholders of Aradigm based on the size of their shareholding:

Grifols SA Corporation
Percentage owned: 34.46% (5.24m shares)
Bleichroeder LP Investment Advisor
Percentage owned: 22.18% (3.38m shares)
Hudson (Frederick M) Individual Investor
Percentage owned: 1.48% (226k shares)
Gonda (Igor) Individual Investor
Percentage owned: 1.01% (154k shares)
Froehlich (Juergen Kurt) Individual Investor
Percentage owned: 1% (153k shares)
Similar to ARDMQ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.